Inovio receives authorization to conduct phase 3 efficacy trial of its covid-19 dna vaccine candidate, ino-4800

Plymouth meeting, pa., aug. 26, 2021 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced that it has received regulatory authorization from brazil's anvisa (agÊncia nacional de vigilÂncia sanitÁria), the national health regulatory agency of brazil, to initiate the global phase 3 segment of its phase 2/3 trial, innovate ( in ovio i no -4800 va ccine t rial for e fficacy), for ino-4800, its dna vaccine candidate for covid-19.
INO Ratings Summary
INO Quant Ranking